Market Size & Trends
The UK continuous glucose monitoring devices market size was valued at USD 532.2 million in 2024 and is expected to reach USD 1.95 billion by 2033, growing at a CAGR of 15.5% from 2025 to 2033. The UK continuous glucose monitoring (CGM) devices market is growing due to rising diabetes prevalence, increasing demand for real-time glucose monitoring, and NHS support for CGM adoption, especially among insulin-treated Type 1 and Type 2 patients. Technological advancements, such as long-lasting sensors, smartphone integration, and non-invasive devices, further drive market penetration. Companies like Abbott, Dexcom, and newcomers like Yuwell are making CGMs more accessible and affordable. Government-backed initiatives focusing on prevention, remission, and personalized diabetes management also contribute to market expansion.New research from the University of Leicester’s Diabetes Research Centre highlights the significant benefits of continuous glucose monitoring (CGM) for individuals with Type 2 diabetes in the UK, while also revealing barriers to its widespread adoption. CGM devices, usually worn on the arm, allow real-time tracking of blood glucose levels, enabling quicker, more accurate treatment decisions. The study, published in Diabetic Medicine, confirms that CGMs help reduce episodes of high and low blood sugar, support lifestyle improvements, and provide doctors with actionable data. However, it also identifies a lack of adequate training among healthcare professionals and resistance to new workflows as major hindrances.
More than 3.6 million people in the UK are living with diabetes, with about 90% diagnosed with Type 2. This chronic condition, though manageable through medication and lifestyle changes, remains a leading cause of preventable complications such as vision loss, kidney failure, and cardiovascular disease.
UK Continuous Glucose Monitoring Devices Market Report Scope Segmentation
This report forecasts revenue growth at the country level and analyzes the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the UK CGM devices market report based on product, connectivity, indication and end use.Product Outlook (Revenue, USD Million, 2021 - 2033)
- Standalone CGM Devices
- Devices
- Consumables (Receivers, Sensors, and Transmitters)
- Integrated CGM-Insulin Pump Systems
Connectivity Outlook (Revenue, USD Million, 2021 - 2033)
- Bluetooth
- 4G/Cellular
- NFC (Near Field Communication)
Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Type 1 Diabetes
- Type 2 Diabetes
End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmacies
- E-commerce
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. UK CGM Devices Market Variables, Trends, & Scope
Chapter 4. UK CGM Devices Market: Product Estimates & Trend Analysis
Chapter 5. UK CGM Devices Market: Connectivity Estimates & Trend Analysis
Chapter 6. UK CGM Devices Market: Indication Estimates & Trend Analysis
Chapter 7. UK CGM Devices Market: End Use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Abbott
- Dexcom
- Roche
- Medtronic
- Senseonics
- GlucoRx
- GlySens
- Nemaura Medical
- Ascensia
- Vively Health Pty Ltd
